{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:21:42Z","timestamp":1773274902989,"version":"3.50.1"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,12,15]],"date-time":"2011-12-15T00:00:00Z","timestamp":1323907200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1007\/s11899-011-0107-9","type":"journal-article","created":{"date-parts":[[2011,12,14]],"date-time":"2011-12-14T08:22:25Z","timestamp":1323850945000},"page":"78-86","source":"Crossref","is-referenced-by-count":27,"title":["Transformation of a Chronic Myeloproliferative Neoplasm to Acute Myelogenous Leukemia: Does Anything Work?"],"prefix":"10.1007","volume":"7","author":[{"given":"Madappa N.","family":"Kundranda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raoul","family":"Tibes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruben A.","family":"Mesa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,12,15]]},"reference":[{"key":"107_CR1","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"\u2022 Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the world health organization (who) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 2009;114:937\u2013951. This key reference addresses the current diagnostic WHO criteria changes for the diagnosis of MPNs.","journal-title":"Blood"},{"key":"107_CR2","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1182\/blood.V6.4.372.372","volume":"6","author":"W Dameshek","year":"1951","unstructured":"Dameshek W. Some speculations on the myeloproliferative syndromes. Blood. 1951;6:372\u20135.","journal-title":"Blood"},{"key":"107_CR3","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054\u201361.","journal-title":"Lancet"},{"key":"107_CR4","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","volume":"434","author":"C James","year":"2005","unstructured":"James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144\u20138.","journal-title":"Nature"},{"key":"107_CR5","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779\u201390.","journal-title":"N Engl J Med"},{"key":"107_CR6","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"RL Levine","year":"2005","unstructured":"Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387\u201397.","journal-title":"Cancer Cell"},{"key":"107_CR7","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.leukres.2006.12.002","volume":"31","author":"RA Mesa","year":"2007","unstructured":"Mesa RA, Verstovsek S, Cervantes F, et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (POST-PV MF), post essential thrombocythemia myelofibrosis (POST-ET MF), blast phase pmf (PMF-BP): Consensus on terminology by the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Leukemia Res. 2007;31:737\u201340.","journal-title":"Leukemia Res"},{"key":"107_CR8","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1182\/blood-2004-07-2864","volume":"105","author":"RA Mesa","year":"2005","unstructured":"Mesa RA, Li CY, Ketterling RP, et al. Leukemic transformation in myelofibrosis with myeloid metaplasia: A single-institution experience with 91 cases. Blood. 2005;105:973\u20137.","journal-title":"Blood"},{"key":"107_CR9","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1182\/blood-2004-09-3426","volume":"105","author":"G Finazzi","year":"2005","unstructured":"Finazzi G, Caruso V, Marchioli R, et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood. 2005;105:2664\u201370.","journal-title":"Blood"},{"key":"107_CR10","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1200\/JCO.2010.29.8711","volume":"29","author":"A Tefferi","year":"2011","unstructured":"Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol. 2011;29:573\u201382.","journal-title":"J Clin Oncol"},{"key":"107_CR11","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1126\/science.1071545","volume":"296","author":"DS Aaronson","year":"2002","unstructured":"Aaronson DS, Horvath CM. A road map for those who don\u2019t know JAK-STAT. Science. 2002;296:1653\u20135.","journal-title":"Science"},{"key":"107_CR12","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1182\/blood-2007-08-107748","volume":"111","author":"R Tiedt","year":"2008","unstructured":"Tiedt R, Hao-Shen H, Sobas MA, et al. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood. 2008;111:3931\u201340.","journal-title":"Blood"},{"key":"107_CR13","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/j.leukres.2006.01.008","volume":"30","author":"RA Mesa","year":"2006","unstructured":"Mesa RA, Powell H, Lasho T, et al. JAK2(V617F) and leukemic transformation in myelofibrosis with myeloid metaplasia. Leukemia Res. 2006;30:1457\u201360.","journal-title":"Leukemia Res"},{"key":"107_CR14","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/sj.leu.2405097","volume":"22","author":"A Tefferi","year":"2008","unstructured":"Tefferi A, Lasho TL, Huang J, et al. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia. 2008;22:756\u201361.","journal-title":"Leukemia"},{"key":"107_CR15","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1182\/blood-2006-12-062125","volume":"110","author":"A Theocharides","year":"2007","unstructured":"Theocharides A, Boissinot M, Girodon F, et al. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood. 2007;110:375\u20139.","journal-title":"Blood"},{"key":"107_CR16","doi-asserted-by":"crossref","first-page":"a4665","DOI":"10.1182\/blood.V110.11.4665.4665","volume":"110","author":"SI Swierczek","year":"2007","unstructured":"Swierczek SI, Yoon D, Prchal JT. Blast transformation in a patient with primary myelofibrosis initiated from JAK2 V617F progenitor. Blood. 2007;110:a4665.","journal-title":"Blood"},{"key":"107_CR17","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1182\/blood-2008-02-138230","volume":"112","author":"CS Tam","year":"2008","unstructured":"Tam CS, Nussenzveig RM, Popat U, et al. The natural history and treatment outcome of blast phase BCR-ABL\u2013 myeloproliferative neoplasms. Blood. 2008;112:1628\u201337.","journal-title":"Blood"},{"key":"107_CR18","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1532\/LH96.10018","volume":"17","author":"R Lopes da Silva","year":"2011","unstructured":"Lopes da Silva R, Ribeiro P, Lourenco A, et al. What is the role of JAK2V617F mutation in leukemic transformation of myeloproliferative neoplasms? Lab Hematol. 2011;17:12\u20136.","journal-title":"Lab Hematol"},{"key":"107_CR19","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1182\/blood-2009-08-236596","volume":"115","author":"PA Beer","year":"2010","unstructured":"Beer PA, Delhommeau F, LeCouedic JP, et al. Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood. 2010;115:2891\u2013900.","journal-title":"Blood"},{"key":"107_CR20","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1182\/blood-2009-09-245381","volume":"115","author":"FX Schaub","year":"2010","unstructured":"Schaub FX, Looser R, Li S, et al. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood. 2010;115:2003\u20137.","journal-title":"Blood"},{"key":"107_CR21","first-page":"1841","volume":"22","author":"R Kralovics","year":"2008","unstructured":"Kralovics R. Genetic complexity of myeloproliferative neoplasms Leukemia. 2008;22:1841\u20138.","journal-title":"Genetic complexity of myeloproliferative neoplasms. Leukemia"},{"key":"107_CR22","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","volume":"356","author":"LM Scott","year":"2007","unstructured":"Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356:459\u201368.","journal-title":"N Engl J Med"},{"key":"107_CR23","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1182\/blood-2007-07-101576","volume":"111","author":"D Pietra","year":"2008","unstructured":"Pietra D, Li S, Brisci A, et al. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood. 2008;111:1686\u20139.","journal-title":"Blood"},{"key":"107_CR24","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2353\/jmoldx.2008.080015","volume":"10","author":"A Pancrazzi","year":"2008","unstructured":"Pancrazzi A, Guglielmelli P, Ponziani V, et al. A sensitive detection method for MPLW515l or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction. J Mol Diagn. 2008;10:435\u201341.","journal-title":"J Mol Diagn"},{"key":"107_CR25","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","volume":"3","author":"Y Pikman","year":"2006","unstructured":"Pikman Y, Lee BH, Mercher T, et al. MPLW515l is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3:e270.","journal-title":"PLoS Med"},{"key":"107_CR26","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1126\/science.1170116","volume":"324","author":"M Tahiliani","year":"2009","unstructured":"Tahiliani M, Koh KP, Shen Y, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. 2009;324:930\u20135.","journal-title":"Science"},{"key":"107_CR27","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/leu.2009.47","volume":"23","author":"A Tefferi","year":"2009","unstructured":"Tefferi A, Pardanani A, Lim KH, et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia. 2009;23:905\u201311.","journal-title":"Leukemia"},{"key":"107_CR28","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1038\/leu.2009.141","volume":"23","author":"N Carbuccia","year":"2009","unstructured":"Carbuccia N, Murati A, Trouplin V, et al. Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia. 2009;23:2183\u20136.","journal-title":"Leukemia"},{"key":"107_CR29","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1038\/leu.2010.65","volume":"24","author":"J Boultwood","year":"2010","unstructured":"Boultwood J, Perry J, Zaman R, et al. High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression. Leukemia. 2010;24:1139\u201345.","journal-title":"Leukemia"},{"issue":"21","key":"107_CR30","doi-asserted-by":"crossref","first-page":"e198","DOI":"10.1182\/blood-2010-06-292433","volume":"117","author":"H Makishima","year":"2011","unstructured":"Makishima H, Jankowska AM, McDevitt MA, et al. CBL, CBLB, TET2, ASXL1, and IDH1\/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Blood. 2011;117(21):e198\u2013206.","journal-title":"Blood"},{"key":"107_CR31","doi-asserted-by":"crossref","unstructured":"Abdel-Wahab O, Pardanani A, Patel J, et al. Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia 2011","DOI":"10.1038\/leu.2011.58"},{"key":"107_CR32","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nature08617","volume":"462","author":"L Dang","year":"2009","unstructured":"Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462:739\u201344.","journal-title":"Nature"},{"key":"107_CR33","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1084\/jem.20092506","volume":"207","author":"S Gross","year":"2010","unstructured":"Gross S, Cairns RA, Minden MD, et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med. 2010;207:339\u201344.","journal-title":"J Exp Med"},{"key":"107_CR34","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/leu.2010.163","volume":"24","author":"A Pardanani","year":"2010","unstructured":"Pardanani A, Lasho T, Finke C, et al. LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations. Leukemia. 2010;24:1713\u20138.","journal-title":"Leukemia"},{"key":"107_CR35","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/leu.2010.99","volume":"24","author":"R Jager","year":"2010","unstructured":"Jager R, Gisslinger H, Passamonti F, et al. Deletions of the transcription factor IKAROS in myeloproliferative neoplasms. Leukemia. 2010;24:1290\u20138.","journal-title":"Leukemia"},{"key":"107_CR36","first-page":"560","volume":"64","author":"EE Osgood","year":"1964","unstructured":"Osgood EE. Contrasting incidence of acute monocytic and granulocytic leukemias in p32-treated patients with polycythemia vera and chronic lymphocytic leukemia. J Lab Clin Med. 1964;64:560\u201373.","journal-title":"J Lab Clin Med"},{"key":"107_CR37","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1007\/s00259-003-1270-6","volume":"30","author":"C Parmentier","year":"2003","unstructured":"Parmentier C. Use and risks of phosphorus-32 in the treatment of polycythaemia vera. Eur J Nucl Med Mol Imaging. 2003;30:1413\u20137.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"107_CR38","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1046\/j.0007-1048.2001.03331.x","volume":"116","author":"MC Petti","year":"2002","unstructured":"Petti MC, Latagliata R, Spadea T, et al. Melphalan treatment in patients with myelofibrosis with myeloid metaplasia. Br J Haematol. 2002;116:576\u201381.","journal-title":"Br J Haematol"},{"key":"107_CR39","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1055\/s-2006-942762","volume":"32","author":"JJ Kiladjian","year":"2006","unstructured":"Kiladjian JJ, Rain JD, Bernard JF, et al. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia. Semin Thromb Hemost. 2006;32:417\u201321.","journal-title":"Semin Thromb Hemost"},{"key":"107_CR40","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood.V90.9.3370","volume":"90","author":"Y Najean","year":"1997","unstructured":"Najean Y, Rain JD. Treatment of polycythemia vera: The use of hydroxyurea and pipobroman in 292 patients under the age of 65\u00a0years. Blood. 1997;90:3370\u20137.","journal-title":"Blood"},{"key":"107_CR41","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1001\/jama.289.13.1645","volume":"289","author":"MH Steinberg","year":"2003","unstructured":"Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: Risks and benefits up to 9\u00a0years of treatment. JAMA. 2003;289:1645\u201351.","journal-title":"JAMA"},{"key":"107_CR42","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1002\/cncr.23505","volume":"112","author":"J Huang","year":"2008","unstructured":"Huang J, Li CY, Mesa RA, et al. Risk factors for leukemic transformation in patients with primary myelofibrosis. Cancer. 2008;112:2726\u201332.","journal-title":"Cancer"},{"key":"107_CR43","first-page":"3630","volume":"91","author":"G Barosi","year":"1998","unstructured":"Barosi G, Ambrosetti A, Centra A, et al. Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Italian cooperative study group on myeloid with myeloid metaplasia. Blood. 1998;91:3630\u20136.","journal-title":"Blood"},{"key":"107_CR44","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/cncr.22021","volume":"107","author":"RA Mesa","year":"2006","unstructured":"Mesa RA, Nagorney DS, Schwager S, et al. Palliative goals, patient selection, and perioperative platelet management: Outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer. 2006;107:361\u201370.","journal-title":"Cancer"},{"key":"107_CR45","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1046\/j.0007-1048.2001.03319.x","volume":"116","author":"JC Wang","year":"2002","unstructured":"Wang JC, Chen W, Nallusamy S, et al. Hypermethylation of the P15INK4b and P16INK4a in agnogenic myeloid metaplasia (AMM) and AMM in leukaemic transformation. Br J Haematol. 2002;116:582\u20136.","journal-title":"Br J Haematol"},{"key":"107_CR46","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1182\/blood-2010-03-274811","volume":"116","author":"S Thepot","year":"2010","unstructured":"\u2022 Thepot S, Itzykson R, Seegers V, et al. Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). Blood 2010;116:3735\u20133742. This is first therapy paper that demonstrates success using azacitidine in treating patients with MPNs that had transformed to AML.","journal-title":"Blood"},{"key":"107_CR47","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.beha.2005.07.009","volume":"19","author":"B Scott","year":"2006","unstructured":"Scott B, Deeg HJ. Hemopoietic cell transplantation as curative therapy of myelodysplastic syndromes and myeloproliferative disorders. Best Pract Res Clin Haematol. 2006;19:519\u201333.","journal-title":"Best Pract Res Clin Haematol"},{"key":"107_CR48","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.bbmt.2006.10.030","volume":"13","author":"BL Scott","year":"2007","unstructured":"Scott BL, Storer BE, Greene JE, et al. Marrow fibrosis as a risk factor for posttransplantation outcome in patients with advanced myelodysplastic syndrome or acute myeloid leukemia with multilineage dysplasia. Biol Blood Marrow Transplant. 2007;13:345\u201354.","journal-title":"Biol Blood Marrow Transplant"},{"key":"107_CR49","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1586\/ehm.09.73","volume":"3","author":"A Ramakrishnan","year":"2010","unstructured":"Ramakrishnan A, Sandmaier BM. Optimizing reduced-intensity conditioning regimens for myeloproliferative neoplasms. Expert Rev Hematol. 2010;3:23\u201333.","journal-title":"Expert Rev Hematol"},{"key":"107_CR50","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1200\/JCO.2008.21.7356","volume":"27","author":"A Tefferi","year":"2009","unstructured":"Tefferi A, Verstovsek S, Barosi G, et al. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol. 2009;27:4563\u20139.","journal-title":"J Clin Oncol"},{"key":"107_CR51","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1182\/blood.V96.12.4007","volume":"96","author":"A Tefferi","year":"2000","unstructured":"Tefferi A, Elliot MA. Serious myeloproliferative reactions associated with the use of thalidomide in myelofibrosis with myeloid metaplasia. Blood. 2000;96:4007.","journal-title":"Blood"},{"key":"107_CR52","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1182\/blood-2006-02-004572","volume":"108","author":"A Tefferi","year":"2006","unstructured":"Tefferi A, Cortes J, Verstovsek S, et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood. 2006;108:1158\u201364.","journal-title":"Blood"},{"key":"107_CR53","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1200\/JCO.2010.31.1175","volume":"29","author":"R Bejar","year":"2011","unstructured":"Bejar R, Levine R, Ebert BL. Unraveling the molecular pathophysiology of myelodysplastic syndromes. J Clin Oncol. 2011;29:504\u201315.","journal-title":"J Clin Oncol"},{"key":"107_CR54","doi-asserted-by":"crossref","unstructured":"Eghtedar A, Verstovsek S, Cortes JE, et al. Phase II study of the JAK2 inhibitor, INCB018424, in patients with refractory leukemias including post-myeloproliferative disorder (MPD) acute myeloid leukemia (SAML) (Abstract 509). Blood 2010.","DOI":"10.1182\/blood.V116.21.509.509"},{"key":"107_CR55","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1158\/1078-0432.CCR-10-2745","volume":"17","author":"PM LoRusso","year":"2011","unstructured":"LoRusso PM, Rudin CM, Reddy JC, et al. Phase I trial of hedgehog pathway inhibitor VISMODEGIB (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res. 2011;17:2502\u201311.","journal-title":"Clin Cancer Res"},{"key":"107_CR56","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1056\/NEJMoa0905360","volume":"361","author":"DD Hoff Von","year":"2009","unstructured":"Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009;361:1164\u201372.","journal-title":"N Engl J Med"},{"key":"107_CR57","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1200\/JCO.2008.17.2064","volume":"26","author":"AW Tolcher","year":"2008","unstructured":"Tolcher AW, Mita A, Lewis LD, et al. Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol. 2008;26:5198\u2013203.","journal-title":"J Clin Oncol"},{"key":"107_CR58","doi-asserted-by":"crossref","unstructured":"Tibes R, McDonagh KT, Lekakis L, et al. Phase I study of the novel survivin and CDC2\/CDK1 inhibitor terameprocol in patients with advanced leukemias. Blood 2009; ASH Annual Meeting Abstract #1039.","DOI":"10.1182\/blood.V114.22.1039.1039"},{"key":"107_CR59","first-page":"314","volume":"116","author":"AM Vannucchi","year":"2010","unstructured":"Vannucchi AM, Guglielmelli P, Lupo L, et al. A phase 1\/2 study of RAD001, an mTOR inhibitor, in patients with myelofibrosis: Final results. ASH Annual Meeting Abstracts. 2010;116:314.","journal-title":"ASH Annual Meeting Abstracts"},{"key":"107_CR60","first-page":"308","volume":"114","author":"J Mascarenhas","year":"2009","unstructured":"Mascarenhas J, Wang X, Rodriguez A, et al. A phase I study of LBH589, a novel histone deacetylase inhibitor in patients with primary myelofibrosis (PMF) and post-polycythemia\/essential thrombocythemia myelofibrosis (post-PV\/ET MF). ASH Annual Meeting Abstracts. 2009;114:308.","journal-title":"ASH Annual Meeting Abstracts"},{"key":"107_CR61","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1182\/blood-2007-07-104455","volume":"112","author":"A Rambaldi","year":"2008","unstructured":"Rambaldi A, Dellacasa CM, Salmoiraghi S, et al. A phase 2a study of the histone-deacetylase inhibitor ITF2357 in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Blood. 2008;112:100.","journal-title":"Blood"},{"key":"107_CR62","doi-asserted-by":"crossref","first-page":"33242","DOI":"10.1074\/jbc.M109.010231","volume":"284","author":"G Saberwal","year":"2009","unstructured":"Saberwal G, Horvath E, Hu L, et al. The interferon consensus sequence binding protein (ICSBP\/IRF8) activates transcription of the FANCF gene during myeloid differentiation. J Biol Chem. 2009;284:33242\u201354.","journal-title":"J Biol Chem"},{"key":"107_CR63","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","volume":"112","author":"JJ Kiladjian","year":"2008","unstructured":"Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferon alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood. 2008;112:3065\u201372.","journal-title":"Blood"},{"key":"107_CR64","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1200\/JCO.2009.23.6075","volume":"27","author":"A Quintas-Cardama","year":"2009","unstructured":"Quintas-Cardama A, Kantarjian H, Manshouri T, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol. 2009;27:5418\u201324.","journal-title":"J Clin Oncol"},{"key":"107_CR65","first-page":"853","volume":"118","author":"I Konieczna","year":"2008","unstructured":"Konieczna I, Horvath E, Wang H, et al. Constitutive activation of Shp2 in mice cooperates with ICSBP deficiency to accelerate progression to acute myeloid leukemia. J Clin Invest. 2008;118:853\u201367.","journal-title":"J Clin Invest"},{"key":"107_CR66","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/j.0902-4441.2006.t01-1-EJH2588.x","volume":"76","author":"R Invernizzi","year":"2006","unstructured":"Invernizzi R, Travaglino E, Benatti C, et al. Survivin expression, apoptosis and proliferation in chronic myelomonocytic leukemia. Eur J Haematol. 2006;76:494\u2013501.","journal-title":"Eur J Haematol"},{"key":"107_CR67","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/leu.2010.113","volume":"24","author":"A Tefferi","year":"2010","unstructured":"Tefferi A, Lasho TL, Abdel-Wahab O, et al. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia. 2010;24:1302\u20139.","journal-title":"Leukemia"},{"key":"107_CR68","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJMc0910063","volume":"362","author":"A Green","year":"2010","unstructured":"Green A, Beer P. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N Engl J Med. 2010;362:369\u201370.","journal-title":"N Engl J Med"},{"key":"107_CR69","doi-asserted-by":"crossref","first-page":"5201","DOI":"10.1182\/blood-2009-06-223982","volume":"114","author":"Y Ding","year":"2009","unstructured":"Ding Y, Harada Y, Imagawa J, et al. AML1\/RUNX1 point mutation possibly promotes leukemic transformation in myeloproliferative neoplasms. Blood. 2009;114:5201\u20135.","journal-title":"Blood"},{"issue":"12","key":"107_CR70","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","volume":"363","author":"S Verstovsek","year":"2010","unstructured":"Verstovsek S, Kantarjian H, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363(12):1117\u201327.","journal-title":"N Engl J Med"},{"issue":"21","key":"107_CR71","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1182\/blood.V116.21.313.313","volume":"116","author":"S Verstovsek","year":"2010","unstructured":"Verstovsek S, Passamonti F, et al. Durable Responses with the JAK1\/ JAK2 Inhibitor, INCB018424, In Patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory or Intolerant to Hydroxyurea (HU). Blood. 2010;116(21):313. ASH Annual Meeting Abstracts.","journal-title":"Blood"},{"issue":"7","key":"107_CR72","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1200\/JCO.2010.32.8021","volume":"29","author":"A Pardanani","year":"2011","unstructured":"Pardanani A, Gotlib JR, Jamieson C, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol. 2011;29(7):789\u201396.","journal-title":"J Clin Oncol"},{"issue":"21","key":"107_CR73","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1182\/blood.V116.21.3082.3082","volume":"116","author":"S Verstovsek","year":"2010","unstructured":"Verstovsek S, Deeg HJ, et al. Phase 1\/2 Study of SB1518, a Novel JAK2\/FLT3 Inhibitor, In the Treatment of Primary Myelofibrosis. Blood. 2010;116(21):3082. ASH Annual Meeting Abstracts.","journal-title":"Blood"},{"issue":"11","key":"107_CR74","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1182\/blood.V112.11.99.99","volume":"112","author":"AR Moliterno","year":"2008","unstructured":"Moliterno AR, Roboz GJ, et al. An Open-Label Study of CEP-701 in Patients with JAK2 V617F-Positive Polycythemia Vera and Essential Thrombocytosis. Blood. 2008;112(11):99. ASH Annual Meeting Abstracts.","journal-title":"Blood"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-011-0107-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-011-0107-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-011-0107-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,28]],"date-time":"2020-06-28T20:05:26Z","timestamp":1593374726000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-011-0107-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,15]]},"references-count":74,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["107"],"URL":"https:\/\/doi.org\/10.1007\/s11899-011-0107-9","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,15]]}}}